このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Keros Therapeutics マネジメント

マネジメント基準チェック /24

Keros Therapeutics'の CEO はJas Seehraで、 Dec2015年に任命され、の在任期間は 8.5年です。の年間総報酬は$ 8.93Mで、 7.3%給与と92.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.7%を直接所有しており、その価値は$ 11.27M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と4.3年です。

主要情報

Jas Seehra

最高経営責任者

US$8.9m

報酬総額

CEO給与比率	7.3%
CEO在任期間	8.8yrs
CEOの所有権	0.7%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27

Keros Therapeutics prices equity offering at $50

Nov 13

CEO報酬分析

Keros Therapeutics の収益と比較して、Jas Seehra の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$168m
Mar 31 2024	n/a	n/a	-US$160m
Dec 31 2023	US$9m	US$649k	-US$153m
Sep 30 2023	n/a	n/a	-US$142m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$116m
Dec 31 2022	US$6m	US$611k	-US$105m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$7m	US$557k	-US$59m
Sep 30 2021	n/a	n/a	-US$61m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$10m	US$521k	-US$45m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$23m
Dec 31 2019	US$695k	US$485k	-US$14m

報酬と市場: Jasの総報酬 ($USD 8.93M ) は、 US市場 ($USD 5.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Jasの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jas Seehra (68 yo)

8.8yrs

在職期間

US$8,932,076

報酬

Dr. Jasbir S. Seehra, also known as Jas, Ph D., has been Chief Executive Officer and Director at Keros Therapeutics Inc., since December 2015 and is its Chair of the Board since July 1, 2024 and was its Pr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jasbir Seehra	CEO & Chair of the Board	8.8yrs	US$8.93m	0.67% $ 14.3m
Christopher Rovaldi	President & COO	2.6yrs	US$4.69m	0% $ 0
Keith Regnante	Chief Financial Officer	4.6yrs	US$2.20m	0% $ 0
Esther Cho	Senior VP	4.4yrs	データなし	データなし
Robin Wagner	Senior Vice President of Human Resources	3.3yrs	データなし	データなし
John Oram	Senior Vice President of Program & Portfolio Management	1.4yrs	データなし	データなし

3.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: KROSの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jasbir Seehra	CEO & Chair of the Board	8.8yrs	US$8.93m	0.67% $ 14.3m
Carl Gordon	Independent Director	4.5yrs	US$409.37k	データなし
Tomer Kariv	Independent Director	4.7yrs	US$385.86k	データなし
Jean-Jacques Bienaime	Lead Independent Director	less than a year	データなし	0.00053% $ 11.2k
Julius Knowles	Independent Director	8.4yrs	US$388.48k	0.0032% $ 67.1k
Mary Gray	Independent Director	3.8yrs	US$396.98k	0.12% $ 2.4m
Ran Nussbaum	Independent Director	8.4yrs	US$390.56k	0% $ 0
Alpna Seth	Independent Director	1.3yrs	US$1.02m	0.044% $ 940.9k
Nima Farzan	Independent Director	4.5yrs	US$388.48k	0.094% $ 2.0m
Mary Bouxsein	Member of Scientific Advisory Board	no data	データなし	データなし
Vicki Rosen	Member of Scientific Advisory Board	no data	データなし	データなし
Paul Yu	Member of Scientific Advisory Board	no data	データなし	データなし

4.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: KROSの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Keros Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Chief Financial Officer notifies of intention to sell stock

Insufficient new directors

Chief Financial Officer notifies of intention to sell stock

Recent updates

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$158k worth of stock

Chief Scientific Officer exercised options and sold US$133k worth of stock

Keros Therapeutics, Inc. Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Chief Scientific Officer exercised options and sold US$527k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Consultant Claudia Ordonez has left the company

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Microcap Value Index

Keros Therapeutics, Inc. Announces Preliminary Results from Its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

Chief Scientific Officer notifies of intention to sell stock

Keros Therapeutics, Inc. Presents Data from the ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of KER-012

Chief Scientific Officer exercised options and sold US$132k worth of stock

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$316k worth of stock

Chief Scientific Officer exercised options and sold US$340k worth of stock

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Keros Therapeutics, Inc. Announces Results from Preclinical Studies of KER-050 and ALK2 Inhibitor Program

New 90-day low: US$55.25

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Keros Therapeutics, Inc. Announces Board Changes

New 90-day high: US$79.96

マネジメント基準チェック /24